I mean, it just that, that, that whole summary just kind of underscores how complex and opaque the whole drug pricing and drug supply chain system is. And that's one thing we learned from the work of the task force is, you know, As public policymakers and regulators, it's difficult to understand where to focus on the supply chain. Everyone's pointing fingers at everyone else. There's a lack of information, there's a lack of transparency. (32:02–32:12)
CLAIM
Asserts that policymakers and regulators struggle to identify focus areas in the drug supply chain due to its complexity.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
